Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Related Keywords

Texas ,United States ,Prithviraj Bose ,University Of Texas Md Anderson Cancer Center ,Division Of Cancer Medicine ,Department Of Leukemia ,Cancer Medicine ,Cancer Center ,Myeloproliferative Neoplasms ,Myelofibrosis ,Mdanderson ,Spleen Volume ,Asco 2023 ,Zilurgisertib ,Ruxolitinib ,Anemia ,